Early proof of concept and IND-enabling studies

Experimentica specializes in the development of preclinical ocular models and in testing ophthalmic drug candidates. Our teams offer deep scientific expertise and advanced technical platforms used in efficacy evaluation. We combine validated disease models with advanced imaging, functional, behavioral, and histological read-outs to generate reliable results and conclusions. Whether your goal is early candidate screening with a pilot study or a fully-powered, pivotal proof-of-concept study, we bring the right designs and insights as well as operational flexibility to meet the needs of sponsors.

Validated models with translational value

Our preclinical models are carefully developed and validated to replicate key aspects of ocular diseases in vitro and in vivo in mice, rats, and rabbits. This translational relevance enhances the predictive power of your nonclinical data and helps reduce downstream development risk. Our model portfolio includes:

• Retinal degeneration and neovascularization (wet AMD, dry AMD, diabetic retinopathy)
• Ocular inflammation and autoimmune uveitis
• Glaucoma, ocular hypertension, and neuroprotection
• Dry eye disease

Our experts advise our clients on model customization and study designs to align with their drug candidate’s route of administration and mechanism of action, enabling them to move from discovery through IND-enabling studies with efficiency and confidence.

Advanced drug delivery capabilities

We specialize in precise drug delivery across all major ocular compartments. Our scientists have a long track record administering a wide range of drug types, including small molecules, biologics, gene therapy, cell therapy, and sustained-release formulations. Noticeable routes of administration include eye drops, intravitreal, subretinal, suprachoroidal, intracameral, and subconjunctival injections of drugs, implants, and grafts.

Endpoints that matter

We offer an extensive suite of ocular read-outs designed to demonstrate therapeutic effects:

• Spectral domain optical coherence tomography (SD-OCT)
• Electroretinography (ERG)
• Fundus imaging & fluorescein angiography
• Intraocular pressure (IOP) measurement
• Histology, immunohistochemistry, and cell-specific staining
• AI-driven image analysis and morphometry
• Western Blot, ELISA, and qPCR

Our scientists will help you select the optimal endpoints based on your target, delivery route, and regulatory pathway.

From discovery to IND – a seamless collaboration

Experimentica is your scientific and strategic partner in the development of your Ophthalmology drug candidates. We collaborate with sponsors to shorten the path from early discovery through IND by aligning efficacy data with pharmacokinetics, safety pharmacology, and exploratory toxicology. Our multidisciplinary approach minimizes study redundancy, reduces timelines, and strengthens the overall nonclinical data package.

Related